Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study

Christophe Cellier(Assistance Publique – Hôpitaux de Paris), Ralph Raymond, Nadine Cerf–Bensussan(Université Paris Cité), Govind Bhagat(Columbia University Irving Medical Center), Francisco León(University of California San Diego), Amélie Trinquand(Hôpital Necker-Enfants Malades), Raquel Perez Maseda, Laura Varela Crespo(Instituto Cajal), Tom van Gils(University of Gothenburg), Valerie Byrnes, David S. Sanders(Sheffield Teaching Hospitals NHS Foundation Trust), Hetty J. Bontkes, Shérine Khater(Hôpital Européen Georges-Pompidou), Marios Hadjivassiliou(Royal Hallamshire Hospital), Keijo Viiri(Tampere University Hospital), Michel Azizi(Inserm), Bana Jabrì(University of Chicago), Olivier Hermine(Centre National de la Recherche Scientifique), Carlota García‐Hoz(Universidad Autónoma de Madrid), Samuli Rounioja, Elizabeth Macintyre(Inserm), Jack D. Bui(University of California San Diego), Georgia Malamut(Délégation Paris 5), Peter H.R. Green(Columbia University Irving Medical Center), Eric Butz(Allogene Therapeutics (United States)), Pekka Collin(Tampere University), Wayne Tsuji(University of California San Diego), Michael Schümann(Charité - Universitätsmedizin Berlin), Joseph A. Murray(Johns Hopkins University), Ciarán P. Kelly(Met Éireann), George Vlad, Anne Blanchard(Délégation Paris 5), Knut EA Lundin, Sheila E. Crowe(University of California, San Diego), Ashleigh Palmer, Gerd Bouma(Amsterdam University Medical Centers), Garbiñe Roy Ariño, BE Llewellyn(Délégation Paris 5), Jane R. Parnes(Stanford University), Bertrand Meresse(Centre Hospitalier Universitaire de Lille), Chris J. Mulder(Amsterdam UMC Location Vrije Universiteit Amsterdam), Anthony J. DiMarino(Thomas Jefferson University)
˜The œLancet. Gastroenterology & hepatology
September 4, 2019
Cited by 101


Related Papers